Eric Warren, Chief Commercial Officer at Esperion Therapeutics, Inc. (ESPR), sold 2,433 shares at $1.49 ($4K) on 2025-03-18, disclosed to the SEC on 2025-03-19.
Seasonal sale ($4k) by Chief Commercial Officer — this insider has traded ESPR in March in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| MLYS | SELL | 2026-07-23 | $200K | — | Filing → |
| MLYS | SELL | 2026-06-30 | $2.7M | — | Filing → |
| ESPR | SELL | 2025-04-21 | $106 | — | Filing → |